Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

durvalumab MeSH Supplementary Concept Data 2025


MeSH Supplementary
durvalumab
Unique ID
C000613593
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000613593
Entry Term(s)
Imfinzi
MEDI-4736
MEDI4736
Pharm Action
Antineoplastic Agents, Immunological
Registry Numbers
28X28X9OKV
0
Heading Mapped to
*Antibodies, Monoclonal
Frequency
513
Note
an IgG1 that targets programmed cell death 1 ligand 1 (PD-L1); enhances the immune response to tumor cells and is used for the treatment of locally advanced or metastatic urothelial carcinoma
Source
Lancet Oncol. 2016 Mar;17(3):299-308.
Date of Entry
2017/01/22
Revision Date
2019/10/31
durvalumab Preferred
MEDI4736 Narrower
Imfinzi Narrower
page delivered in 0.005s